(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release →
Posted in Business, Denmark, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Cardior Pharmaceuticals, Christoph Broja, Claudia Ulbrich, Denmark, EQT, EQT Life Sciences, Germany, Heart Diseases, Novo Nordisk, partnership, Professor Thomas Thum, RNA Therapies, sustainability